公开(公告)号：WO1996015229A1

公开(公告)日：1996-05-23

申请号：PCT/IB1995001003

申请日：1995-11-13

Applicant: SYSTEMIX, INC. ,  HANSON CENTRE FOR CANCER RESEARCH

Inventor： SYSTEMIX, INC. ,  HANSON CENTRE FOR CANCER RESEARCH ,  HILL, Beth, L. ,  CHEN, Benjamin, P. ,  SIMMONS, Paul, J.

IPC: C12N05/08

CPC classification number: A61K35/28 ,  C07K16/28 ,  C12N5/0647 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2502/1394

Abstract: A method for obtaining human hematopoietic stem cells is provided by enrichment for stem cells using a novel stem cell marker.

Abstract translation: 通过使用新型干细胞标记物对干细胞进行富集来提供获得人造血干细胞的方法。

公开(公告)号：WO1995034676A1

公开(公告)日：1995-12-21

申请号：PCT/US1995003038

申请日：1995-03-09

Applicant: SYSTEMIX, INC. ,  GALY, Anne, H., M. ,  MULE, James, J.

Inventor： SYSTEMIX, INC.

IPC: C12Q01/00

CPC classification number: G01N33/56977 ,  A61K2035/124 ,  A61K2039/5154 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/25 ,  C12N2501/26 ,  C12N2501/33 ,  C12N2502/1394 ,  C12N2510/00 ,  G01N33/56972

Abstract: The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.

Abstract translation: 本发明涉及基于细胞特异性标记物富集骨髓和/或淋巴祖细胞的造血细胞群的方法。 这些方法还提供了缺乏长期造血重建潜力的丰富的前胸淋巴细胞定居祖细胞群。 由本发明提供的富含细胞和细胞群的组合物也由本发明提供。 还包括细胞的使用方法。 提供遗传修饰细胞的方法，就像从其获得的细胞一样。

公开(公告)号：WO1995003693A1

公开(公告)日：1995-02-09

申请号：PCT/US1994008574

申请日：1994-07-29

Applicant: SYSTEMIX, INC.

Inventor： SYSTEMIX, INC. ,  PEAULT, Bruno ,  UCHIDA, Nobuko

IPC: A01N01/02

CPC classification number: C12N5/0647 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2502/1394

Abstract: A method for obtaining human hematopoietic stem cells is provided by separation of the stem cells from dedicated cells by virtue of a novel stem cell marker. The cells obtained are provided. The isolated cells demonstrate increased proliferative potential.

Abstract translation: 通过新型干细胞标记物将干细胞从专用细胞中分离出来，获得人造血干细胞的方法。 提供获得的细胞。 分离的细胞表现出增加的增殖潜力。

公开(公告)号：WO2018223830A1

公开(公告)日：2018-12-13

申请号：PCT/CN2018/087402

申请日：2018-05-18

Applicant: 广州白泽科技有限公司

Inventor： 黄兵

IPC: C12N5/0775 ,  A61K9/19 ,  A61K35/28 ,  A61P17/00

CPC classification number: A61K9/0021 ,  A61K9/19 ,  A61K35/28 ,  C12N5/0668 ,  C12N2500/14 ,  C12N2500/30 ,  C12N2500/40 ,  C12N2501/12 ,  C12N2501/22 ,  C12N2501/2306 ,  C12N2501/24

Abstract: 提供了一种人间充质干细胞外泌体冻干粉的制备方法，包括以下步骤：1)人间充质干细胞的培养、纯化及传代；2)诱导人间充质干细胞大量合成和分泌有功能的外泌体；3)超滤浓缩人间充质干细胞外泌体，制得浓缩培养液并进行冷藏；4)将冷藏后的所述浓缩培养液制备成冻干粉，向所述冻干粉中添加复合液进行保存。

公开(公告)号：WO2018216021A1

公开(公告)日：2018-11-29

申请号：PCT/IL2018/050571

申请日：2018-05-24

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： LANDSMAN, Limor ,  EPSHTEIN, Alona

IPC: C12N5/071 ,  A61K35/12 ,  A61K35/39

CPC classification number: A61K35/39 ,  C12N5/0676 ,  C12N2501/105 ,  C12N2501/2306

Abstract: A method of promoting in vitro beta cell proliferation is provided. The method comprises subjecting beta cells to an effective amount of at least one growth factor expressed by pancreatic pericytes during the neonatal period, thereby promoting in vitro beta cell proliferation.

公开(公告)号：WO2017194924A1

公开(公告)日：2017-11-16

申请号：PCT/GB2017/051282

申请日：2017-05-09

Applicant: THE UNIVERSITY OF BIRMINGHAM

Inventor： CHEN, Frederick ,  FRUMENTO, Guido ,  MOSS, Paul Austin Henry

IPC: C12N5/0783

CPC classification number: C12N5/0636 ,  C12N5/0087 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00

Abstract: Provided is a method of sorting T cells based on expression of CD117. The T cells may comprise a nucleotide sequence encoding a TCR and/or a CAR. Prior to sorting, the cells may have undergone reversion to a naïve phenotype. Also provided is a method of generating T cells having a naïve phenotypewhich comprises culturing central memory and/or effector memory T cells in a culture medium comprising a cytokine. Cell populations and uses of the T cells in therapy are also described.

Abstract translation: 提供了基于CD117的表达对T细胞进行分选的方法。 T细胞可以包含编码TCR和/或CAR的核苷酸序列。 在分选之前，细胞可能已经经历了逆转为无显着表型。 还提供了产生具有表型的T细胞的方法，其包括在包含细胞因子的培养基中培养中枢记忆和/或效应记忆T细胞。 还描述了细胞群体和T细胞在治疗中的用途。

公开(公告)号：WO2017042814A1

公开(公告)日：2017-03-16

申请号：PCT/IL2016/051001

申请日：2016-09-08

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： REISNER, Yair ,  ZLOTNIKOV KLIONSKY, Yael ,  NATHANSOHN-LEVI, Bar ,  YARIMI, Liran ,  KAGAN, Sivan

IPC: C12N5/0784 ,  A61K39/00 ,  A61K35/15 ,  A61P37/00

CPC classification number: C12N5/064 ,  A01K67/0271 ,  A01K2267/0331 ,  A01K2267/0368 ,  A61K39/0008 ,  A61K2039/5154 ,  C12N2501/02 ,  C12N2501/04 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/71

Abstract: A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of perforin+ immature DCs (Perf+ im DCs), thereby treating the inflammation in the subject. Methods of generating Perf+ im DCs, wherein the Perf+ im DCs are inhibited from maturing are also disclosed. Isolated population of cells, pharmaceutical compositions and articles of manufacture are also disclosed.

Abstract translation: 公开了治疗需要的受试者的炎症的方法。 该方法包括向受试者施用治疗有效量的穿孔素+未成熟DC（Perf + im DC），从而治疗受试者的炎症。 还公开了生成Perf + im DCs的方法，其中Perf + im DC被抑制成熟。 还公开了分离的细胞群，药物组合物和制品。

公开(公告)号：WO2016176651A3

公开(公告)日：2016-12-01

申请号：PCT/US2016030281

申请日：2016-04-29

Applicant: HUTCHINSON FRED CANCER RES

Inventor： DELANEY COLLEEN ,  RIDDELL STANLEY R

IPC: A61K35/17 ,  A61K39/395 ,  C12N15/00

CPC classification number: C12N15/86 ,  A61K39/0011 ,  A61K2039/5156 ,  C12N5/0647 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/42 ,  C12N2501/599 ,  C12N2510/00 ,  C12N2740/16043 ,  C12N2740/16045 ,  C12N2810/6081

Abstract: Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to activate, promote proliferation of, detect, enrich, isolate, track, deplete and/or eliminate modified cells. The cells can also be modified to express a binding domain.

Abstract translation: 血细胞干/祖细胞（HSPC）和/或非T效应细胞被修饰以表达包括标签盒的细胞外成分。 标签盒可用于激活，促进增殖，检测，富集，分离，追踪，消耗和/或消除修饰细胞。 细胞也可以被修饰以表达结合结构域。

公开(公告)号：WO2016127259A1

公开(公告)日：2016-08-18

申请号：PCT/CA2016/050128

申请日：2016-02-11

Applicant: THE HOSPITAL FOR SICK CHILDREN

Inventor： POST, Martin ,  LITVACK, Michael

IPC: C12N5/0786 ,  A61K35/15 ,  A61P11/00 ,  C12N5/0789 ,  C12N5/10

CPC classification number: C12N5/0645 ,  A61K35/15 ,  C12N5/0606 ,  C12N2500/90 ,  C12N2500/92 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/33 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturmg the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

Abstract translation: 提供肺泡样巨噬细胞和从成血成血管细胞产生肺泡样巨噬细胞的方法。 该方法包括以下步骤：i）在包含血管内皮生长因子（VEGF），干细胞因子（SCF）和白细胞介素-3（IL-3）的造血诱导培养基中培养成血成血管细胞足够的时间以产生 巨噬细胞，以及ii）在合适的条件下培养包含粒细胞巨噬细胞集落刺激因子（GM-CSF）和任选的巨噬细胞集落刺激因子（M-CSF）的肺泡巨噬细胞诱导培养基中的巨噬细胞并持续足够的时间 产生肺泡样巨噬细胞。

公开(公告)号：WO2016109661A1

公开(公告)日：2016-07-07

申请号：PCT/US2015/068055

申请日：2015-12-30

Applicant: ANTHROGENESIS CORPORATION

Inventor： MURPHY, Brian ,  VOSKINARIAN-BERSE, Vanessa ,  NORDBERG, Andrea ,  WILSON, Keith ,  KANG, Lin

IPC: A61K35/51 ,  A61K35/50 ,  A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K35/50 ,  A61K35/51 ,  C07D473/00 ,  C12N5/0646 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2506/11

Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK ce3lls and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.

Abstract translation: 本文提供了使用具有干细胞移动因子的培养基的三阶段扩增和分化方法来生产天然杀伤（NK）细胞的方法。 本文还提供了使用由本文所述的三阶段方法产生的NK细胞和NK细胞群以及治疗患有癌症或病毒感染的个体的方法来抑制肿瘤细胞增殖的方法，包括施用NK细胞和/ 通过本文描述的三阶段方法产生的NK细胞群体具有癌症或病毒感染的个体。